Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases

Advances in Antiplatelet Therapy: Agents in Clinical Development

(2009) Dominick J. Angiolillo et al.   AMERICAN JOURNAL OF CARDIOLOGY

Rationale and Design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study

(2009) Michael G. Hennerici   CEREBROVASCULAR DISEASES

TP Receptor Antagonism: A New Concept in Atherothrombosis and Stroke Prevention

(2009) Angel Chamorro   CEREBROVASCULAR DISEASES

New P2Y12 antagonists

(2009) Alan D Michelson   CURRENT OPINION IN HEMATOLOGY

Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779

(2009) J. L. DIENER et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial

(2009) Gilles Montalescot et al.   LANCET

Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study

(2009) Richard C Becker et al.   LANCET

Ticagrelor — Is There Need for a New Player in the Antiplatelet-Therapy Field?

(2009) Albert Schömig   NEW ENGLAND JOURNAL OF MEDICINE

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

(2009) Lars Wallentin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of platelet aggregation with prasugrel and clopidogrel: An integrated analysis in 846 subjects

(2009) Ying G. Li et al.   PLATELETS

The aptamer ARC1779 is a potent and specific inhibitor of von willebrand factor mediatedex vivoplatelet function in acute myocardial infarction

(2009) Alexander O. Spiel et al.   PLATELETS

The effect of antiplatelet drugs clopidogrel and aspirin is less immediately after stent implantation

(2009) Jolanta M. Siller-Matula et al.   THROMBOSIS RESEARCH

Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura

(2009) Paul Knöbl et al.   TRANSFUSION

Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel

(2008) Jolanta M. Siller-Matula et al.   AMERICAN HEART JOURNAL

Future innovations in anti-platelet therapies

(2008) N E Barrett et al.   BRITISH JOURNAL OF PHARMACOLOGY

Guide to Receptors and Channels (GRAC), 3rd edition

(2008) S P H Alexander et al.   BRITISH JOURNAL OF PHARMACOLOGY

Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38

(2008) Stephen D. Wiviott et al.   CIRCULATION

Von Willebrand Factor in Cardiovascular Disease

(2008) Alexander O. Spiel et al.   CIRCULATION

Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial

(2008) S. A. Murphy et al.   EUROPEAN HEART JOURNAL

Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity

(2008) Samuel Chackalamannil et al.   JOURNAL OF MEDICINAL CHEMISTRY

Basic and Translational Research on Proteinase-Activated Receptors: Antagonism of the Proteinase-Activated Receptor 1 for Thrombin, a Novel Approach to Antiplatelet Therapy for Atherothrombotic Disease

(2008) Madhu Chintala et al.   JOURNAL OF PHARMACOLOGICAL SCIENCES

Calcium-Channel Blockers Reduce the Antiplatelet Effect of Clopidogrel

(2008) Jolanta M. Siller-Matula et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

The reversible P2Y12antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function

(2008) N. L. DOVLATOVA et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The active metabolite of prasugrel effectively blocks the platelet P2Y12receptor and inhibits procoagulant and pro-inflammatory platelet responses

(2008) Heather M. Judge et al.   PLATELETS

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (II): Pharmacodynamic and pharmacokinetic characterization

(2008) Joseph M. Post et al.   THROMBOSIS RESEARCH

Novel P2Y12 adenosine diphosphate receptor antagonists for inhibition of platelet aggregation (I): In vitro effects on platelets

(2008) Judi Bryant et al.   THROMBOSIS RESEARCH

Platelet ADP-receptor antagonists for cardiovascular disease: past, present and future

(2008) Nina C Raju et al.   Nature clinical practice. Cardiovascular medicine

Novel uses for anti-platelet agents as anti-inflammatory drugs

(2007) S C Pitchford   BRITISH JOURNAL OF PHARMACOLOGY

Prasugrel, a New Thienopyridine Antiplatelet Drug, Weakly Inhibits Cytochrome P450 2B6 in Humans

(2007) Nag A. Farid et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

(2007) Steven R. Steinhubl et al.   THROMBOSIS RESEARCH